Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon is attractive because its upstream C1q platform addresses the initiating driver of classical complement disease, giving ANX005, ANX007, ANX1502, and ANX009 a differentiated mechanism that could translate into broad efficacy while preserving non-target pathways. The investment case is further supported by two major catalysts: tanruprubart’s BLA submission in GBS, where a 241-patient Phase 3 and FORWARD bridging study with 10/10 patients improving quickly strengthen approvability, and ARCHER II’s 659-patient readout in 4Q26, where statistical significance may be achievable even if the Phase 2-like ~73% relative reduction regresses. Financially, the shares appear backed by meaningful optionality, with around $225M in cash at 1Q26, runway into 2H27, and market dynamics in GBS and GA that could materially expand value if either program converts.

Annexon is viewed negatively because its lead asset, vonaprument, is carrying a highly uncertain Phase 3 setup after failing the Phase 2 ARCHER primary endpoint on GA lesion growth, making replication of the earlier vision-preservation signal difficult in a field where no drug has yet shown a clear vision benefit. The company also faces meaningful execution and commercialization risk: tanruprubart still needs regulatory approval in the U.S. and EU, the GA market already has two approved competitors that generated about $1.1B in combined 2025 sales, and Annexon has not launched any products. Financially, 2Q26 OpEx was $57M, net loss was $53M, cash was $209M, and while the July $50M draw supports runway into 2028, ongoing losses and potential additional dilutive financing remain a clear overhang.